ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "morbidity and mortality and rheumatoid arthritis (RA)"

  • Abstract Number: 29 • 2016 ACR/ARHP Annual Meeting

    Risk of Vascular Mortality in Seniors with New-Onset Rheumatoid Arthritis

    Jessica Widdifield1, Michael Paterson2, Anjie Huang3, Bindee Kuriya4, Carter Thorne5, Janet E. Pope6, Claire Bombardier7 and Sasha Bernatsky8, 1McGill University, Toronto, ON, Canada, 2Institute of Clinical Evaluative Sciences, Toronto, ON, Canada, 3Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 4Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, 5University of Toronto and Southlake Regional Health Centre, Newmarket, ON, Canada, 6University of Western Ontario, St Joseph's Health Care, London, ON, Canada, 7University of Toronto, Toronto, ON, Canada, 8Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose: RA patients are known to be at increased risk of vascular morbidity and mortality, although conflicting reports exist for incident RA patients. Our aim…
  • Abstract Number: 30 • 2016 ACR/ARHP Annual Meeting

    Impact of Interstitial Lung Disease on Mortality of Patients with Rheumatoid Arthritis

    Dam Kim1, Soo-Kyung Cho2, Chan-Bum Choi3, Jung-Yoon Choe4, Won Tae Chung5, Seung-Jae Hong6, Young Ok Jung7, Tae-Hwan Kim8, Tae-Jong Kim9, Hye-Soon Lee10, Joo Hyun Lee11, Jisoo Lee12, Shin-Seok Lee13, Dae-Hyun Yoo14, Bo Young Yoon15, Jin Woo Song16, Sang-Cheol Bae17 and Yoon-Kyoung Sung1, 1Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, The Republic of, 3Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 4Medicine, Catholic university of Daegu School of medicine, Daegu, Korea, The Republic of, 5Rheumatology, Dong-A University Hospital, Busan, South Korea, 6Dept. of Rheumatology, #1 Hoeg, KyungHee University Medical Center, SEOUL, South Korea, 7Internal Medicine, Hallym University Kangnam Sacred Heart Hospital, Seoul, South Korea, 8Department of Rheumatology, Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 9Chonnam Nat`l University Medical School&Hospital, Chonnam, South Korea, 10Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 11Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 12Int Medicine, Ewha Woman's Univ Schl of Med, Seoul, Korea, Republic of, 13Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Korea, The Republic of, 14Division of Rheumatology, Department of Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 15Rheumatology/Internal medicine, Inje Iniversity Ilsan Paik Hospital, Goyang, Korea, The Republic of, 16Department of pulmonary and critical care of medicine, Asan medical center, University of Ulsan, College of Medicine, Seoul, Korea, The Republic of, 17Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, Korea, The Republic of

    Background/Purpose:   Some studies have supported ethnicity-related differences in the prevalence of ILD and ILD in RA; however, these results have not yet been conclusive.…
  • Abstract Number: 40 • 2015 ACR/ARHP Annual Meeting

    Increased Mortality in Indigenous North Americans Persons with Rheumatoid Arthritis Is Partially Explained By Psychiatric and Physical Comorbidity: a Population Based Study

    Carol Hitchon1, Sazzadul Khan2, Brenda Elias3, Alan Katz4 and Christine A. Peschken5, 1Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, 2Manitoba Centre for Health Policy and Research, University of Manitoba, Winnipeg, MB, Canada, 3Community Health Sciences, University of Manitoba, Winnipeg, MB, Canada, 4Manitoba Centre for Health Policy, University of Manitoba, Winnipeg, MB, Canada, 5Arthritis Center, University of Manitoba, Winnipeg, MB, Canada

    Background/Purpose: Rheumatoid Arthritis (RA) is associated with excess mortality.  Indigenous North Americans (INA) in our region have high RA prevalence rates and young age at onset yet experience…
  • Abstract Number: 580 • 2015 ACR/ARHP Annual Meeting

    Treatment with Biologic Agents in Rheumatoid Arthritis and Mortality Risk in Clinical Practice

    Leticia Leon1, Luis Rodriguez-Rodriguez1, Alejandro Gomez-Gomez2, Pilar Macarrón2, Margarita Blanco2, Juan A Jover2 and Lydia Abasolo1, 1Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, 2Rheumatology, Hospital Clínico San Carlos, Madrid, Spain

    Background/Purpose: It is a well-known fact the decline of life expectancy in Rheumatoid Arthritis (RA) being the increased mortality in these patients a constant concern…
  • Abstract Number: 1343 • 2015 ACR/ARHP Annual Meeting

    Mortality Due to Sepsis in Patients with Rheumatoid Arthritis

    Orit Barrett1, Ella Abramovich2, Jacob Dreiher3, Victor Novack4 and Mahmoud Abu-Shakra5, 1Department of Medicine D, Soroka Medical Center and Ben-Gurion University, Beersheba, Israel, 2Department of Medicine D, Soroka University Medical Center and Ben-Gurion University, Beersheba, Israel, 3Clalit Health Services, Ben-Gurion University of the Negev, Beer Sheva,,, BeerSheba, Israel, 4Clinical Research Center, Soroka Medical Center and Ben-Gurion University, Beersheba, Israel, 5Rheumatic Diseases Unit, Soroka Medical Center and Ben-Gurion University, Beer-Sheva, Israel

    Background/Purpose: Severe infections contribute significantly to the morbidity and mortality of patients with rheumatoid arthritis. The aim of the study was to  identify the characteristics…
  • Abstract Number: 1534 • 2015 ACR/ARHP Annual Meeting

    Temporal Trends and Outcomes of Acute Myocardial Infarction in Rheumatoid Arthritis Hospitalizations

    Narender Annapureddy1, Achint Patel2, Rabi Yacoub3, Krishna Pakanati4, Shiv Agarwal5, Priya Simoes6, Shaan Patel3, Sunil Kamat7, Alexandre Benjo8 and Girish Nadkarni9, 1Rheumatology and Immunology, Vanderbilt University, Nashville, TN, 2Public Health, Icahn School of Medicine at Mount Sinai, New York, NY, 3Icahn School of Medicine at Mount Sinai, New York, NY, 4Gateway Medical Center, Clarksville, TN, 5Cardiology, University of Arkansas Medical Sciences, Little Rock, AR, 6Internal Medicine, St.Lukes Roosevelt Hospital Center at Mount Sinai, New York, NY, 7Critical Care, Kokilaben Dhirubhai Ambani Hospital and Medical Research Institute, Mumbai, India, 8Ochsner Clinic Foundation, New Orleans, NY, 9Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risk of cardiac mortality. With better treatment modalities, some studies suggest that infarction (AMI) mortality in RA…
  • Abstract Number: 1562 • 2015 ACR/ARHP Annual Meeting

    Clinical Correlates, Outcomes and Predictors of Episcleritis and Scleritis Associated with Rheumatoid Arthritis

    Cristian Caimmi1, Wendy M. Smith2, Cynthia S. Crowson3, Eric L. Matteson4 and Ashima Makol5, 1Unit of Rheumatology, Department of Medicine,, University of Verona, Verona, Italy, 2Department of Ophthalmology, Mayo Clinic, Rochester, MN, 3Division of Rheumatology and Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 4Division of Rheumatology, Department of Internal Medicine and Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 5Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, MN

    Background/Purpose: Inflammatory ocular disease (IOD) has traditionally been regarded as a severe extra-articular manifestation of rheumatoid arthritis (RA) with high mortality. This study aims to…
  • Abstract Number: 1999 • 2015 ACR/ARHP Annual Meeting

    Improvement in Mortality in RA Compared to the General Population – Closing the Mortality Gap

    Diane Lacaille1,2, Eric C. Sayre3 and Michal Abrahamowicz4, 1Rheumatology, University of British Columbia, Vancouver, BC, Canada, 2Rheumatology, Arthritis Research Canada, Richmond, BC, Canada, 3Arthritis Research Canada, Richmond, BC, Canada, 4Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada

    Background/Purpose: Increased mortality in RA is believed to be a consequence of inflammation. With improved treatment, mortality would be expected to decrease over time. The…
  • Abstract Number: 3237 • 2015 ACR/ARHP Annual Meeting

    Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA?

    Elena Myasoedova1, Cynthia S. Crowson2, Eric L. Matteson3, John M. Davis III4, Terry M. Therneau5 and Sherine E. Gabriel6, 1Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, 2Health Sciences Research, Mayo Clinic, Rochester, MN, 3Rheumatology, Mayo Clinic, Rochester, MN, 4Division of Rheumatology, Mayo Clinic, Rochester, MN, 5Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 6Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ

    Background/Purpose: Rheumatoid arthritis (RA) is associated with increased cardiovascular (CV) morbidity and mortality as compared to the general population. Recent prospective studies with limited follow-up…
  • Abstract Number: 3239 • 2015 ACR/ARHP Annual Meeting

    Response to Methotrexate Predicts Mortality in Rheumatoid Arthritis up to 30 Years

    Carolin Krause1, Siegfried Wassenberg2, Rolf Rau3, Gertraud Herborn4, Juergen Braun5 and Dietmar Krause6, 1University Munster, Munster, Germany, 2Rheumaklinik, Themistocles Gluck hospital - Rheumazentrum Ratingen, Ratingen, Germany, 3Expert in Rheumatology, Düsseldorf, Germany, 4Evangelisches Fachkrankenhaus Ratingen, Ratingen, Greece, 5Rheumazentrum Ruhrgebiet, Herne, Germany, 6Dept. for Medical Informatics, Biometry and Epidemiology, Ruhr University, Bochum, Germany

    Background/Purpose: Methotrexate (MTX) is considered as the anchor drug for the treatment of patients with rheumatoid arthritis (RA). MTX has been shown to reduce disease…
  • Abstract Number: 2116 • 2014 ACR/ARHP Annual Meeting

    Hospitalization Rates and Utilization Among Rheumatoid Arthritis Patients: A Population-Based Study from 1987 to 2012

    C. John Michet III1, Katrina Strobova2, Sara J. Achenbach3, Cynthia S. Crowson4 and Eric L. Matteson5, 1Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, 2Department of Medicine, Charles University, Prague, Czech Republic, 3Department of Health Sciences Research, Mayo Clinic, Rochester, MN, 4Health Sciences Research, Mayo Clinic, Rochester, MN, 5Rheumatology, Mayo Clinic, Rochester, MN

    Background/Purpose Patients with rheumatoid arthritis (RA) experience chronic management issues and are at risk for complex comorbidities. It is unknown, however, to what extent the…
  • Abstract Number: 2053 • 2014 ACR/ARHP Annual Meeting

    Mortality Decreases in Patients with Rheumatoid Arthritis: a 15-Year Prospective Cohort Study

    Joëlle van den Hoek1,2, Hendriek C. Boshuizen3, Leo D. Roorda4, Gerard J. Tijhuis5, Mike T. Nurmohamed5, Trudi van den Bos2 and Joost Dekker6,7, 1Rehabilitation Research Center, Reade, Rehabilitation | Rheumatology, Amsterdam, Netherlands, 2Social Medicine, Academic Medical Center, Amsterdam, Netherlands, 3National Institute of Public Health and the Environment, Bilthoven, Netherlands, 4Amsterdam Rehabilitation Research Center | Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, 5Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, 6Rehabilitation Medicine, Psychiatry and EMGO Institute for Health and Care Research, VU University Medical Center, Amsterdam, Netherlands, 7Reade, centre for Rehabilitation and Rheumatology, Amsterdam, Netherlands

    Background/Purpose Patients with rheumatoid arthritis (RA) have a higher mortality risk than the general population, with similar patterns over the last decades. However, more recent…
  • Abstract Number: 1416 • 2014 ACR/ARHP Annual Meeting

    Analysis of Cardiac Involvement in Patients with Amyloid a (AA) Amyloidosis Due to Rheumatoidarthritis

    Daisuke Kobayashi1, Satoshi Ito1, Satoru Kodama1, Akira Murasawa1, Ichiei Narita2 and Kiyoshi Nakazono1, 1Niigata Rheumatic Center, Shibata, Japan, 2Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

    Background/Purpose Rheumatoid arthritis (RA) is one of the major causes of amyloid A (AA) amyloidosis. The major organs affected are the kidneys and gastrointestinal (GI)…
  • Abstract Number: 1068 • 2014 ACR/ARHP Annual Meeting

    Smoking-Related Mortality in Rheumatoid Arthritis: A Retrospective Cohort Study Using Electronic Medical Records

    Rebecca M Joseph1, Mohammad Movahedi2 and Deborah PM Symmons1,2, 1NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom, 2Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom

    Background/Purpose Smoking is a known risk factor for rheumatoid arthritis (RA) and there is evidence suggesting that many patients with RA continue to smoke. The…
  • Abstract Number: 1067 • 2014 ACR/ARHP Annual Meeting

    Mortality Trends in Rheumatoid Arthritis during the Biologic Era, 1998 to 2011

    Bryant R. England1, Harlan Sayles2, Ted R. Mikuls2 and Kaleb Michaud1,3, 1Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 2Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 3National Data Bank for Rheumatic Diseases, Wichita, KS

    Background/Purpose: Rheumatoid arthritis (RA) has consistently been associated with increased mortality risk, a risk that appears to be linked with greater disease activity. Although there…
  • « Previous Page
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology